Lundbeck makes an offer to buy Prexton Therapeutics for 100M EUR now and will pay up to 805M EUR down the line in case the drug Foliglurax reaches a set of milestones. One of the big winners is the Danish venture capital fund Sunstone Capital who owns approximately one-fifth of Prexton Therapeutics and bought their shares in 2015.
